Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-licensing evaluation of WT-1 Trastuzumab biosimilar in metastatic HER2-positive breast cancer
TCTR20260724003Phase 4Not yet recruiting
- Sponsor
- Chulabhorn Foundation
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by Chulabhorn Foundation. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on TCTR20260724003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260724003.